Financials KPC Pharmaceuticals,Inc

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
22.53 ^CNY	+2.41%		+5.33%	+8.01%

Apr. 19	KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	Kunyao Group Receives Clinical Trial Approval for FMF Drug	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	8,165	6,559	8,379	10,707	15,812	17,058	-	-
Enterprise Value (EV) ¹	8,165	6,559	8,379	10,707	15,812	17,058	17,058	17,058
P/E ratio	18 x	14.4 x	16.5 x	27.7 x	35.4 x	28.3 x	21.2 x	17.9 x
Yield	-	-	-	-	0.96%	1.35%	1.71%	-
Capitalization / Revenue	1.01 x	0.85 x	1.02 x	1.29 x	2.05 x	1.99 x	1.7 x	1.57 x
EV / Revenue	1.01 x	0.85 x	1.02 x	1.29 x	2.05 x	1.99 x	1.7 x	1.57 x
EV / EBITDA	-	9.2 x	10.4 x	15 x	21.1 x	18.5 x	15 x	12.9 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	-	1.47 x	1.75 x	2.15 x	2.98 x	2.93 x	2.6 x	2.35 x
Nbr of stocks (in thousands)	760,948	758,256	758,256	758,256	757,987	757,114	-	-
Reference price ²	10.73	8.650	11.05	14.12	20.86	22.53	22.53	22.53
Announcement Date	3/30/20	3/15/21	3/18/22	3/22/23	3/21/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	8,120	7,717	8,254	8,282	7,703	8,578	10,014	10,842
EBITDA ¹	-	712.9	806.8	713.2	749.2	924.5	1,134	1,327
EBIT ¹	-	540.8	634	497.1	568.5	769.4	1,019	1,211
Operating Margin	-	7.01%	7.68%	6%	7.38%	8.97%	10.17%	11.17%
Earnings before Tax (EBT) ¹	-	540.5	631.3	477.3	563.6	761.4	1,014	1,203
Net income ¹	-	456.9	507.7	383.2	444.7	601.3	805.3	950.4
Net margin	-	5.92%	6.15%	4.63%	5.77%	7.01%	8.04%	8.77%
EPS ²	0.5965	0.6018	0.6695	0.5100	0.5900	0.7960	1.064	1.256
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	0.2000	0.3050	0.3850	-
Announcement Date	3/30/20	3/15/21	3/18/22	3/22/23	3/21/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	10.6%	11%	7.89%	8.64%	10.3%	12.3%	13.1%
ROA (Net income/ Total Assets)	-	-	-	-	4.68%	5.9%	7.16%	7.2%
Assets ¹	-	-	-	-	9,499	10,191	11,247	13,199
Book Value Per Share ²	-	5.870	6.310	6.570	6.990	7.700	8.670	9.580
Cash Flow per Share ²	-	0.5400	0.3300	0.3300	0.4700	0.9100	1.120	1.370
Capex ¹	-	46.6	226	65.5	57.1	132	123	136
Capex / Sales	-	0.6%	2.74%	0.79%	0.74%	1.54%	1.22%	1.25%
Announcement Date	3/30/20	3/15/21	3/18/22	3/22/23	3/21/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.53 CNY

Average target price

25.01 CNY

Spread / Average Target

+11.01%